Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-05-30-Speech-3-019"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20010530.4.3-019"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:translated text |
".
Madam President, I would like to say to Mr Van Velzen that the questions were officially sent to us on Monday 28 May 2001 and that we shall do everything possible to answer them before the end of the week. You shall, therefore, have the answer at the beginning of next week, I assure you, and we will be able to continue the debate on these issues.
With regard to the two more specific questions, Mr Van Velzen has quite rightly mentioned health problems, including both degenerative neurological diseases and cancer problems, and he will see that, if these specific programmes are approved, there is the prospect of carrying out European added-value research on this issue, within the context of genomics and health. For example, there are opportunities in the specific programme to undertake clinical trials for cancer and degenerative diseases, which are some of the new possibilities opened up by genomics. This does not mean, however, that they cannot be begun immediately, since there is an undeniable European added value.
Regarding Article 169, as I mentioned, we have produced a document, which is launching the debate along these lines, and we shall explain why Article 168 is not used in the same way. Mr Van Velzen will be given a very clear answer to this in the answers to the questions."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples